Clinical Trials Arena on MSN
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.
Tezepelumab reduced exacerbations across all seasons in severe uncontrolled asthma, even among patients with perennial and seasonal allergies.
Unlike the West, where smoking remains the dominant driver, India’s COPD burden is shaped by pollution, says Dr Anurag ...
The GOLD COPD Update 2026 provides updated guidance on case-finding, disease activity, exacerbation management.
According to Dr Shibu Vijayan, Chief Medical Officer, Global Health, Qure.ai, the impact of early COPD diagnosis is profound.
Winter acts as a perfect storm for COPD patients. Cold air irritates the airway lining, causing muscles to tighten and making ...
Winter pollution and cold air can sharply worsen COPD symptoms, especially in non-smokers exposed to biomass smoke. Experts ...
India Today on MSN
India's hidden lung crisis: How COPD surged to no. 2 killer in 30 years
Among Indians aged 30 and above, the prevalence is now around 7%. According to the World Health Organisation, COPD symptoms ...
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition that causes breathing difficulties by blocking ...
Chronic obstructive pulmonary disease (COPD) is straining Europe’s healthcare budgets, primarily through preventable ...
COPD remains one of India's most underdiagnosed lung diseases, with millions noticing symptoms only after serious damage.
Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results